Jennifer Champoux Sells 2,175 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares of the company’s stock, valued at $1,247,420. This represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, June 17th, Jennifer Champoux sold 2,176 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total value of $41,344.00.
• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $43,500.00.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ GLUE opened at $22.28 on Friday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The stock has a market cap of $1.88 billion, a PE ratio of -15.05 and a beta of 1.60. The stock has a fifty day moving average of $18.96 and a 200-day moving average of $18.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. On average, sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter worth approximately $30,000. Russell Investments Group Ltd. purchased a new stake in Monte Rosa Therapeutics in the third quarter valued at approximately $32,000. Lazard Asset Management LLC lifted its position in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after purchasing an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after buying an additional 776 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Analyst Ratings Changes

GLUE has been the topic of a number of analyst reports. Wells Fargo & Company decreased their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Guggenheim cut their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. JPMorgan Chase & Co. boosted their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.